Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eiger BioPharmaceuticals (EIGR) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. The post Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today? appeared first on InvestorPlace.…#mintnewmillionaires
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Clinical Trials | Health